Wilmer Cutler Pickering Hale and Dorr advised Eliem Therapeutics on the deal, and Cooley advised Tenet Medicines. Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced that it had entered into...
Eliem Therapeutics’ Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
Eliem Therapeutics’ $60-Million Series B Financing
Brown Rudnick LLP advised Eliem Therapeutics on the deal. Eliem Therapeutics Inc. recently closed on a $60-million Series B financing. Eliem is a clinical-stage biotechnology company...